Article Versions Notes

Shin S-P, Shin K-S, Lee J-M, Jung I-K, Koo J, Lee S-W, Park S, Shin J, Park M, Park B, et al. The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines. 2022; 10(5):712. https://doi.org/10.3390/vaccines10050712

Shin, Seung-Phil, Kwang-Soo Shin, Jeong-Mi Lee, In-Kyung Jung, Jimo Koo, Seung-Woo Lee, Seowoo Park, Jieun Shin, Myunghwan Park, Bongju Park, and et al. 2022. "The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates" Vaccines 10, no. 5: 712. https://doi.org/10.3390/vaccines10050712

Shin, S.-P., Shin, K.-S., Lee, J.-M., Jung, I.-K., Koo, J., Lee, S.-W., Park, S., Shin, J., Park, M., Park, B., Oh, H., Koo, B.-S., Hong, J., Ryu, C.-M., Kim, J.-O., Oh, T., & Kang, C.-Y. (2022). The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. Vaccines, 10(5), 712. https://doi.org/10.3390/vaccines10050712